1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Seegene, Inc.
  6. Summary
    A096530   KR7096530001

SEEGENE, INC.

(A096530)
  Report
End-of-day quote Korea Stock Exchange  -  2022-06-23
37450.00 KRW   +10.64%
05/25Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic
AQ
05/16Seegene, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/13Seegene reports first quarter 2022 financial results
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
06/20/2022 06/21/2022 06/22/2022 06/23/2022 06/24/2022 Date
36550 37050 34700 33850 37450 Last
300967 299011 362060 728184 677623 Volume
-1.75% +1.37% -6.34% -2.45% +10.64% Change
Estimated financial data (e)
Sales 2022 1 133 B 0,88 B 0,88 B
Net income 2022 371 B 0,29 B 0,29 B
Net cash position 2022 657 B 0,51 B 0,51 B
P/E ratio 2022 5,27x
Yield 2022 2,20%
Sales 2023 732 B 0,57 B 0,57 B
Net income 2023 192 B 0,15 B 0,15 B
Net cash position 2023 818 B 0,63 B 0,63 B
P/E ratio 2023 10,2x
Yield 2023 1,87%
Capitalization 1 931 B 1 496 M 1 496 M
EV / Sales 2022 1,12x
EV / Sales 2023 1,52x
Nbr of Employees 928
Free-Float 67,9%
More Financials
Company
Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP)... 
More about the company
Ratings of Seegene, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about SEEGENE, INC.
05/25Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic
AQ
05/16Seegene, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/13Seegene reports first quarter 2022 financial results
AQ
04/26Seegene unveils world's first commercialized '3 Ct' PCR assay
AQ
04/26Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay
CI
04/06Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval
CI
03/17Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary
AQ
03/04Seegene, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.
CI
03/04Seegene, Inc. authorizes a Buyback Plan.
CI
03/02Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business
AQ
02/24Seegene unveils new assay optimized for on-site testing in 'living with Covid-19' era
AQ
02/24Seegene Inc. Unveils New Assay Optimized for On-Site Testing in 'Living with Covid-19' ..
CI
02/17Seegene Announces Q4 and Full-Year 2021 Financial Results
AQ
02/10Seegene Signs Supply Deal to Deliver 4 million COVID-19 Tests to Brazil
AQ
02/10Seegene Signs Supply Deal to Deliver 4 Million Covid-19 Tests to Brazil
CI
More news
News in other languages on SEEGENE, INC.
05/16Seegene, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/26Seegene, Inc. dévoile le premier test PCR '3 Ct' commercialisé au monde
04/06Le test principal Allplex㬱 ; RV de Seegene reçoit l'approbation de la TGA austral..
03/04SEEGENE, INC. (KOSDAQ : A096530) annonce un rachat d'actions pour une valeur de 50 000 mil..
03/04Seegene, Inc. autorise un plan de rachat.
More news
Chart SEEGENE, INC.
Duration : Period :
Seegene, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEEGENE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 37 450,00 KRW
Average target price 55 666,67 KRW
Spread / Average Target 48,6%
EPS Revisions
Managers and Directors
Jong-Yoon Chun Chief Executive Officer & Director
Jin-Soo Choi President & General Manager-Management
Kyung-O Min President & Head-Research
Min-Chul Lee President, Head-Research & Development
Ho Lee President & Head-Sales
Sector and Competitors
1st jan.Capi. (M$)
SEEGENE, INC.-38.61%1 496
EXACT SCIENCES CORPORATION-41.99%7 944
GUARDANT HEALTH, INC.-53.76%4 714
BGI GENOMICS CO., LTD.-22.43%4 174
IOVANCE BIOTHERAPEUTICS, INC.-45.78%1 627
VERACYTE, INC.-44.81%1 625